New York, United States
Biotia is a promising player in the health tech landscape, specializing in infectious disease diagnosis. Founded in 2016 as a spinoff from Cornell Tech, the company harnesses cutting-edge technology, combining next-generation sequencing with artificial intelligence, to offer rapid detection solutions. This potent mix ensures that clinicians and researchers can make better-informed decisions, ultimately enhancing patient treatment and outcomes.
Positioned at the intersection of AI, Biotechnology, Health Care, Clean Energy, and Machine Learning, Biotia operates from its headquarters in the United States. The company's vision—encapsulated in its slogan "Fighting Infectious Diseases, Powered by Genomics + AI"—illustrates its ambitious commitment to technological innovation in healthcare.
In its bid to scale operations and continue innovating, Biotia secured an $8.00M Series A investment on 23 August 2022. Notable investors include Hyperplane, OCA Ventures, Tau Ventures, and the Mayo Clinic Platform, underscoring significant confidence in the company's potential to revolutionize infectious disease management.
